Pfiz­er lines up ac­cess to 'dog­gy­bone DNA' in man­u­fac­tur­ing of mR­NA vac­cines, gene ther­a­pies and more

As Pfiz­er builds a whole fran­chise of ge­net­ic prod­ucts on the cor­ner­stone of its mR­NA Covid-19 vac­cine, it’s test­ing out a new way to man­u­fac­ture them.

Touch­light, which has been net­ting deals in the ever-ex­pand­ing and com­pet­i­tive DNA man­u­fac­tur­ing space, has inked a non-ex­clu­sive patent li­cense agree­ment with Pfiz­er. The deal gives Pfiz­er rights to Touch­light’s en­zy­mat­ic DNA, called dog­gy­bone DNA, or dbD­NA, to man­u­fac­ture and com­mer­cial­ize mR­NA-based vac­cines and ther­a­peu­tics as well as DNA vac­cines and gene ther­a­pies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER